Journal
STEM CELLS
Volume 30, Issue 5, Pages 797-803Publisher
WILEY
DOI: 10.1002/stem.1066
Keywords
Stem cells; Embryonic stem cells; Induced pluripotent stem cells; Cell replacement therapy; Immunogenicity; Transplantation; Tolerance; Rejection; Regenerative medicine
Categories
Funding
- NIH [P20RR018757]
- Rhode Island Foundation
- BD Biosciences
- NSFC [30872346]
- California Institute for Regenerative Medicine [TR1-01277]
- NIH COBRE at Roger Williams Medical Center
Ask authors/readers for more resources
Autologous-induced pluripotent stem cells (iPSCs) may eventually be used in cell replacement therapies to treat a wide range of diseases and have been touted as a solution to the vexing problem of immune rejection in this context. Emerging evidence suggests, however, that ostensibly histocompatible iPSCs may be rejected following transplantation. Here, we review the mechanisms that contribute to immunogenicity in iPSCs and forward approaches to permit their acceptance in potential cell replacement therapies. STEM CELLS 2012;30:797803
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
